Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Amisulpride in Huntington's disease].

Carsten Saft1, Jürgen Andrich, Peter H Kraus

  • 1Neurologische Klinik der Ruhr-Universität Bochum, St. Josef-Hospital, Huntington Zentrum NRW, Bochum. carsten.saft@cityweb.de

Psychiatrische Praxis
|October 13, 2005
PubMed
Summary

Amisulpride effectively treated psychosis in four Huntington's disease patients. However, two patients experienced extrapyramidal side effects, suggesting early sensitivity in these patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Virtual reality-based oculography detects internuclear ophthalmoplegia in multiple sclerosis and other neurological disorders.

Journal of neurology·2026
Same author

Challenges facing genetic diagnostics of Huntington's disease: an update.

Expert review of molecular diagnostics·2026
Same author

The DNA/RNA autophagy protein SIDT2 as a novel neuropathological hallmark in Huntington disease.

Brain pathology (Zurich, Switzerland)·2026
Same author

Loss-of-function variants in the CAPN1 activator CD99L2 cause X-linked spastic ataxia.

Nature communications·2026
Same author

Supplementation with short-chain fatty acids and a prebiotic improves clinical outcome in Parkinson's disease: a randomized double-blind prospective study.

Scientific reports·2025
Same author

Pridopidine in early-stage manifest Huntington's disease: a phase 3 trial.

Nature medicine·2025

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • Huntington's disease (HD) is a neurodegenerative disorder.
  • Psychosis is a potential symptom of HD.
  • Amisulpride is an atypical antipsychotic with a favorable side effect profile.

Observation:

  • Four patients with genetically confirmed Huntington's disease and psychosis were treated with Amisulpride.
  • Clinical and genetic confirmation of Huntington's disease was established for all patients.

Findings:

  • Amisulpride demonstrated antipsychotic efficacy in all four patients.
  • Two patients developed extrapyramidal side effects (EPS) during Amisulpride treatment.
  • The development of EPS suggests early sensitivity in Huntington's disease patients.

Related Experiment Videos

Implications:

  • Striatal neuron degeneration in Huntington's disease may predispose patients to early-onset extrapyramidal side effects from Amisulpride.
  • Careful monitoring for EPS is crucial when prescribing Amisulpride for psychosis in Huntington's disease patients.
  • Further research is warranted to explore optimal antipsychotic strategies for Huntington's disease.